Bharat [BIBCL] vs Dishman Carbogen [DCAL] Detailed Stock Comparison

Bharat Immunologicals & Biologicals Corporation Limited

BSE
Loading...

Dishman Carbogen Amcis Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Bharat Immunologicals & Biologicals Corporation Limited wins in 3 metrics, Dishman Carbogen Amcis Ltd. wins in 14 metrics, with 0 ties. Dishman Carbogen Amcis Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bharat Immunologicals & Biologicals Corporation Limited Dishman Carbogen Amcis Ltd. Better
P/E Ratio (TTM) -4.59 22.30 Dishman Carbogen Amcis Ltd.
Price-to-Book Ratio 0.97 0.42 Dishman Carbogen Amcis Ltd.
Debt-to-Equity Ratio 94.48 40.20 Dishman Carbogen Amcis Ltd.
PEG Ratio -0.08 -0.16 Bharat Immunologicals & Biologicals Corporation Limited
EV/EBITDA -7.13 9.62 Dishman Carbogen Amcis Ltd.
Profit Margin (TTM) -241.59% 4.25% Dishman Carbogen Amcis Ltd.
Operating Margin (TTM) -2,888.44% 3.99% Dishman Carbogen Amcis Ltd.
EBITDA Margin (TTM) N/A 3.99% N/A
Return on Equity -21.00% 0.06% Dishman Carbogen Amcis Ltd.
Return on Assets (TTM) -6.28% 0.03% Dishman Carbogen Amcis Ltd.
Free Cash Flow (TTM) $108.92M $1.58B Dishman Carbogen Amcis Ltd.
1-Year Return -32.86% -33.95% Bharat Immunologicals & Biologicals Corporation Limited
Price-to-Sales Ratio (TTM) 9.97 0.95 Dishman Carbogen Amcis Ltd.
Enterprise Value $1.42B $46.55B Dishman Carbogen Amcis Ltd.
EV/Revenue Ratio 18.52 1.66 Dishman Carbogen Amcis Ltd.
Gross Profit Margin (TTM) N/A 80.34% N/A
Revenue per Share (TTM) $2 $179 Dishman Carbogen Amcis Ltd.
Earnings per Share (Diluted) $-3.59 $7.58 Dishman Carbogen Amcis Ltd.
Beta (Stock Volatility) 0.34 0.40 Bharat Immunologicals & Biologicals Corporation Limited

Bharat Immunologicals & Biologicals Corporation Limited vs Dishman Carbogen Amcis Ltd. Stock Performance Analysis

Loading Price Chart...

BIBCL
DCAL

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bharat Immunologicals & Biologicals Corporation Limited0.71%-1.61%-1.38%5.28%-9.50%-14.68%
Dishman Carbogen Amcis Ltd.-2.38%-2.24%-7.21%9.02%-19.76%-29.73%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bharat Immunologicals & Biologicals Corporation Limited-32.86%-26.70%-80.09%-12.27%29.14%57.16%
Dishman Carbogen Amcis Ltd.-33.95%46.77%-6.77%33.46%290.77%118.12%

Performance & Financial Health Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs Dishman Carbogen Amcis Ltd.

MetricBIBCLDCAL
Market Information
Market Cap i₹762.99M₹26.50B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i35,100337,264
90 Day Avg. Volume i35,515517,904
Last Close₹17.14₹180.24
52 Week Range₹14.10 - ₹25.65₹128.50 - ₹321.95
% from 52W High-33.18%-44.02%
All-Time High₹94.50 (Jun 14, 2021)₹396.40 (Jan 22, 2018)
% from All-Time High-81.86%-54.53%
Growth Metrics
Quarterly Revenue Growth-0.99%0.06%
Quarterly Earnings Growth-1.00%-0.09%
Financial Health
Profit Margin (TTM) i-2.42%0.04%
Operating Margin (TTM) i-28.88%0.04%
Return on Equity (TTM) i-0.21%0.00%
Debt to Equity (MRQ) i94.4840.20
Cash & Liquidity
Book Value per Share (MRQ)₹18.24₹405.67
Cash per Share (MRQ)₹2.07₹40.41
Operating Cash Flow (TTM) i₹87.48M₹-199,700,000
Levered Free Cash Flow (TTM) i₹-166,388,000₹32.40M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A₹0.00

Valuation & Enterprise Metrics Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs Dishman Carbogen Amcis Ltd.

MetricBIBCL (Apr 26, 2026)DCAL (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-4.5922.30
Forward P/E iN/A13.52
PEG Ratio i-0.08-0.16
Price to Sales (TTM) i9.970.95
Price to Book (MRQ) i0.970.42
Market Capitalization
Market Capitalization i₹762.99M₹26.50B
Enterprise Value i₹1.42B₹46.55B
Enterprise Value Metrics
Enterprise to Revenue i18.521.66
Enterprise to EBITDA i-7.139.62
Risk & Other Metrics
Beta i0.340.40
Book Value per Share (MRQ) i₹18.24₹405.67

Financial Statements Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs Dishman Carbogen Amcis Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIBCL (2023)DCAL (2025)
Revenue/Sales i446.09M26.42B
Cost of Goods Sold i422.08M5.26B
COGS % of Revenue i94.6%19.9%
Gross Profit i24.01M21.16B
Gross Margin i5.4%80.1%
Research & Development i0N/A
Operating Income (EBIT) i-160.07M1.46B
Operating Margin i-35.9%5.5%
EBITDA i-154.93M4.83B
EBITDA Margin i-34.7%18.3%
Pre-Tax Income i-222.68M193.10M
Pre-Tax Income % of Revenue i-49.9%0.7%
Income Tax i-56.29M160.70M
Income Tax % of Revenue i-12.6%0.6%
Net Income (Profit) i-166.39M32.40M
Profit Margin i-37.3%0.1%

Balance Sheet & Liquidity Metrics

MetricBIBCL (2023)DCAL (2025)
Cash & Equivalents i12.86M2.86B
Total Current Assets i358.03M22.00B
Total Current Assets % of Revenue i80.3%83.3%
Total Current Liabilities i940.42M19.25B
Total Current Liabilities % of Revenue i210.8%72.9%
Long-Term Debt iN/A13.90B
Long-Term Debt % of Revenue i0.0%52.6%
Total Shareholders Equity i882.14M58.32B
Retained Earnings i-662.11M2.13B
Retained Earnings % of Revenue i-148.4%8.1%
Property, Plant & Equipment i72.02M10.27B

Cash Flow Statement Comparison

MetricBIBCL (2023)DCAL (2025)
Operating Cash Flow i87.48M-199.70M
Operating Cash Flow % of Revenue i19.6%-0.8%
Capital Expenditures i0-2.15B
Free Cash Flow i108.92M1.58B
FCF Margin i24.4%6.0%
Debt Repayment iN/A-1.10B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBIBCLDCAL
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i43.18M156.78M
Float Shares i17.58M54.95M
% Held by Insiders i59.25%69.30%
% Held by Institutions i0.00%2.41%
% Held by Public i40.75%28.29%

Dividend Analysis & Yield Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs Dishman Carbogen Amcis Ltd.

MetricBIBCLDCAL
Last 12-Month Dividend iN/A₹0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A₹0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A₹0.00
Ex-Dividend DateN/AN/A